What is Generalized Anxiety Disorder?
What is Generalized Anxiety Disorder?
Generalized anxiety disorder involves persistent and excessive worry that interferes with daily activities. This ongoing worry and tension may be accompanied by physical symptoms, such as restlessness, feeling on edge or easily fatigued, difficulty concentrating, muscle tension, or problems sleeping. Often the worries focus on everyday things such as job responsibilities, family health, or minor matters such as chores, car repairs, or appointments. GAD can go undiagnosed because of a focus on physical symptoms and the stigma of mental illness. However, people with GAD can have meaningful lives and can function socially as well, when the anxiety level is mild-to-moderate or when they are taking some kind of treatment.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) lists separation anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and an anxiety disorder caused by another medical condition. The criteria of GAD in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months, with at least three of the core symptoms in adults and one sign in the case of children.
According to the Anxiety and Depression Association of America (ADAA), in any given year, GAD affects 6.8 million adults or 3.1% of the US population. Women are twice as likely to be affected. Although the exact cause of GAD is unknown, there is evidence that biological factors, family background, and life experiences, particularly stressful ones, play a role.
What are the Generalized Anxiety Disorder Emerging Drugs?
To meet the current demands of the patient pool and to counter the unmet needs of the therapeutic market, drug developers are gradually shifting their attention toward GAD as a possible indication for new targeted therapies. Several companies are working robustly on many new therapies, such as MM-120 (Mind Med) and PH49B (VistaGen’s Therapeutics). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.
MM-120 (Mind Med) is a pharmacologically optimized form of lysergic acid diethylamide (LSD; it has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions). The drug is a psychedelic drug being developed for GAD and other brain-based disorders and can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM-120 manifests primarily in visual, as well as auditory, hallucinations. MM-120 is currently in Phase II b clinical trial for GAD. MindMed is working with study investigators and clinical trial sites to prepare for participant enrollment, which is expected to start in early 2022.
PH49B (VistaGen’s Therapeutics) is an innovative synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel mechanism of action, PH94B is an odorless nasal spray administered at microgram-level doses to achieve rapid-onset anti-anxiety, or anxiolytic, effects. The pharmacological activity of PH94B is fundamentally differentiated from that of all FDA-approved anti-anxiety drugs. Importantly, PH94B does not require systemic uptake and distribution to produce its rapid-onset anti-anxiety effects. In all clinical trials to date, PH94B’s safety profile has been excellent, with placebo-like side effects and no serious adverse events like those that are associated with the current FDA-approved treatment options. The drug is currently in Phase II for the treatment of generalized anxiety disorder.
Discover which therapies are expected to grab major Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Market Forecast
What is the Generalized Anxiety Disorder Market Size in 7MM?
The total generalized anxiety disorder market size was accounted for USD 1,500 million in the year 2021 and is estimated to grow during the study period (2019-2032).
What is the Generalized Anxiety Disorder Market Outlook?
The Generalized Anxiety Disorder market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Generalized Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. This segment gives a thorough detail of the Generalized Anxiety Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Who are the leading companies in the Generalized Anxiety Disorder Market Landscape?
The key players in the Generalized anxiety disorder market who are in different phases of developing Generalized anxiety disorder Therapies are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics and others.
What are the Key strengths of the Generalized Anxiety Disorder Market Report?
Key strengths of the generalized anxiety disorder Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the generalized anxiety disorder Market.
Which country is expected to account for the most significant prevalent cases for Generalized Anxiety Disorder in the 7MM?
The United States is expected to account for the highest prevalent Generalized Anxiety Disorder cases.
Discover more about drugs for Generalized Anxiety Disorder in development @ Generalized Anxiety Disorder Market Trends
1. Trending Healthcare Market Research Reports
2. Technical Due Diligence Firms
7. B-Cell Maturation Antigen Targeted Therapies Market
9. Oncolytic Virus Cancer Therapy Pipeline
10. Shingles Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
Comments
Post a Comment